Transcriptomics

Dataset Information

0

Suppression of heparan sulfation resensitizes YAP1-driven BRAF mutant melanoma to MAPK pathway inhibitors


ABSTRACT: Preclinical and clinical data implicate the transcriptional co-activator YAP1 in resistance to multiple targeted therapies, including BRAF and MEK inhibitors. However, tumor subtypes driven by YAP1 activity and associated vulnerabilities are poorly defined. Here, we show particularly high YAP1 activity in the MITFlow/AXLhigh subset of melanoma cell lines and patient tumors characterized by resistance to MAPK pathway inhibition and broad receptor tyrosine kinase activity. To uncover genetic dependencies of melanoma cells with high YAP1 activity, we used a genome-wide CRISPR/Cas9 functional screen and identified SLC35B2, the 3′-phosphoadenosine-5′-phosphosulfate transporter of the Golgi apparatus, as an essential gene for YAP1-mediated drug resistance. SLC35B2 expression correlates with tumor progression, and its loss decreases heparan sulfate expression, reduces receptor tyrosine kinase activity, and sensitizes resistant melanoma cells to BRAF inhibition in vitro and in vivo. Thus, SLC35B2 is a target in YAP1-driven BRAF mutant melanoma for overcoming drug resistance to MAPK pathway inhibitors.

ORGANISM(S): Homo sapiens

PROVIDER: GSE193775 | GEO | 2022/08/15

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2019-04-15 | GSE127564 | GEO
2016-07-01 | E-GEOD-73470 | biostudies-arrayexpress
2020-07-07 | PXD012812 | Pride
2020-07-07 | PXD012813 | Pride
2017-09-20 | GSE98314 | GEO
2016-07-01 | GSE73470 | GEO
2014-02-19 | E-GEOD-50509 | biostudies-arrayexpress
2015-09-15 | E-GEOD-65185 | biostudies-arrayexpress
2014-12-03 | E-GEOD-61992 | biostudies-arrayexpress
2015-09-15 | E-GEOD-65184 | biostudies-arrayexpress